Inventor

Jeffrey Schlom

Inventor

Potomac, MD, US

Overview

1986–2021

Patent span

Human necessities

Primary field (CPC A)

Patents· 74 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

A61Kprimary

A61KPreparations for medical, dental or toiletry purposes26%

C07KPeptides23%

A61PSpecific therapeutic activity of chemical compounds or medicinal preparations22%

C12NMicroorganisms or enzymes13%

Y02ATechnologies for adaptation to climate change7%

G01NInvestigating or analysing materials by determining their chemical or physical properties4%

Y10STechnical subjects covered by former uspc cross-reference art collections [xracs] and digests4%

A61NElectrotherapy1%

C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms0%

PatentTitleYear

11,065,313Modified yeast-brachyury immunotherapeutic compositions2021 11,065,318Yeast-MUC1 immunotherapeutic compositions and uses thereof2021 11,034,740Brachyury deletion mutants, non-yeast vectors encoding Brachyury deletion mutants, and their use2021 10,874,729Combination immunotherapy compositions against cancer and methods2020 10,550,164None2020 10,508,141Nucleic acids encoding HLA-A24 agonist epitopes of MUC1-C oncoprotein2019 10,507,235Yeast-based immunotherapy for Chordoma2019 10,383,924Combination immunotherapy compositions against cancer and methods2019 10,363,294Yeast-brachyury immunotherapeutic compositions2019 10,188,714Yeast-MUC1 immunotherapeutic compositions and uses thereof2019 10,138,271Native and agonist CTL epitopes of the MUC1 tumor antigen2018 10,035,832HLA-A24 agonist epitopes of MUC1-C oncoprotein and compositions and methods of use2018 9,804,163'Biomarkers for prostate cancer and methods for their detection'2017 9,725,494'Soluble CD27 (sCD27) and the use thereof'2017 9,623,097'Yeast-brachyury immunotherapeutic compositions'2017 9,533,031'Yeast-MUC1 immunotherapeutic compositions and uses thereof'2017 9,370,559'Human cytotoxic T-lymphocyte epitope and its agonist epitope from the non-variable number of tandem repeat sequence of MUC-1'2016 9,198,941'Yeast-Brachyury immunotherapeutic compositions'2015 9,175,057'Immunogenic peptides and methods of use'2015 8,957,192'Human cytotoxic T-lymphocyte epitope and its agonist epitope from the non-variable number of tandem repeat sequence of MUC-1'2015 8,933,041'System for treating and preventing breast cancer'2015 8,901,093'Custom vectors for treating and preventing pancreatic cancer'2014 8,883,448'Mutated ras peptides for generation of CD8+ cytotoxic T lymphocytes'2014 8,835,167'Humanized anti-tag 72 CC49 for diagnosis and therapy of human tumors'2014 8,828,717'Framework residue substituted humanized COL-1 antibodies and their use'2014 8,748,390'Immunogenic epitopes of NGEP antigen'2014 8,613,933'Brachyury polypeptides and methods for use'2013 8,609,395'Agonist and antagonist peptides of carcinoembryonic antigen (CEA)'2013 8,535,890'Methods to determine immunogenicity of humanized anti-tag 72 CC49 antibodies'2013 8,188,214'Brachyury polypeptides and methods for use'2012 8,178,508'Methods of stimulating an immune response against prostate specific antigen'2012 8,029,788'Variants of humanized anti-carcinoma MAb CC49'2011 7,999,071'Human cytotoxic T-lymphoctye epitope and its agonist eptiope from the non-variable number of tandem repeat sequence of MUC-1'2011 7,919,607'Nucleic acids encoding humanized anti-tag 72 CC49 antbodies'2011 7,915,396'Nucleic acid molecules encoding minimally immunogenic variants of SDR-grafted humanized antibody CC49'2011 7,910,692'Immunogenic peptides and methods of use'2011 7,871,986'Methods of stimulating an immune response against prostate specific antigen'2011 7,855,276'Framework residue substituted humanized COL-1 antibodies and their use'2010 7,771,715'Recombinant vector expressing multiple costimulatory molecules and uses thereof'2010 7,763,719'Variants of humanized anti-carcinoma MAb CC49'2010 7,723,096'Agonist peptides of carcinoembryonic antigen (CEA) and nucleic acid sequences encoding the agonist peptides'2010 7,709,002'Mutated ras peptides for generation of CD8+Cytotoxic T lymphocytes'2010 7,662,395'Method of enhancing a targeted immune response against tumors'2010 7,598,225'Generation of immune response to prostate-specific antigen (PSA)'2009 7,589,181'Minimally immunogenic variants of SDR-grafted humanized antibody CC49 and their use'2009 7,569,673'Humanized anti-tag 72 cc49 for diagnosis and therapy of human tumors'2009 7,547,773'Nucleic acid molecules encoding prostate specific antigen oligo epitope peptides'2009 7,410,644'Recombinant pox virus for immunization against tumor-associated antigens'2008 7,368,116'Method of enhancing a targeted immune response against tumors'2008 7,256,004'Variants of humanized anti-carcinoma monoclonal antibody CC49'2007 7,247,615'Peptide agonists of prostate-specific antigen and uses therefor'2007 7,211,432'Recombinant vector expressing multiple costimulatory molecules and uses thereof'2007 7,179,899'Composite antibodies of humanized human subgroup IV light chain capable of binding to TAG-72'2007 7,118,738'Recombinant pox virus for immunization against MUC1 tumor-associated antigen'2006 6,969,609'Recombinant vector expressing multiple costimulatory molecules and uses thereof'2005 6,946,133'Prostate specific antigen oligo-epitope peptide'2005 6,893,869'Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule'2005 6,818,749'Variants of humanized anti carcinoma monoclonal antibody cc49'2004 6,756,038'Agonist and antagonist peptides of carcinoembryonic antigen (CEA)'2004 6,548,068'Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule'2003 6,495,137'Humanized anti-tag-72 monoclonal antibodies using human subgroup 4 kappa light chains'2002 6,319,496'Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof'2001 6,207,815'Family of high affinity, modified antibodies for cancer treatment'2001 6,165,460'Generation of immune responses to prostate-specific antigen (PSA)'2000 6,051,225'Family of high affinity, modified antibodies for cancer treatment'2000 6,045,802'Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule'2000 6,001,349'Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof'1999 5,993,813'Family of high affinity, modified antibodies for cancer treatment'1999 5,892,019'Production of a single-gene-encoded immunoglobulin'1999 5,698,530'Recombinant virus expressing human carcinoembryonic antigen and methods of use thereof'1997 5,512,443'Second generation monoclonal antibodies having binding specificity to TAG-72 and human carcinomas and methods for employing the same'1996 5,472,693'Family of anti-carcinoembryonic antigen chimeric antibodies'1995 5,183,756'Monoclonal antibody (D612) having selective reactivity for gastrointestinal caricinomas and method for employing the same'1993 4,612,282'Monoclonal antibodies reactive with human breast cancer'1986

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1986–2021Patents assigned to US HEALTH (65)· patent assignee history

1986Based in Vienna, VA, US· patent location history

1993–2021Based in Potomac, MD, US· patent location history

1995–2002Patents assigned to DOW CHEMICAL CO (5)· patent assignee history

2000–2005Based in Potamac, MD, US· patent location history

2012–2019Patents assigned to SCHLOM JEFFREY (14)· patent assignee history

2012–2015Patents assigned to TSANG KWONG-YOK (8)· patent assignee history

2015–2021Patents assigned to GLOBEIMMUNE INC (10)· patent assignee history

Inventor activity

Assignee and location history derived from the patent record.

Assignees

Assignee	Patents	Span
US HEALTH	65	1986–2021
SCHLOM JEFFREYself	14	2012–2019
GLOBEIMMUNE INC	10	2015–2021
TSANG KWONG-YOK	8	2012–2015
DOW CHEMICAL CO	5	1995–2002

Locations

Location	Patents	Span
Potomac, Maryland, US	70	1993–2021
Potamac, Maryland, US	3	2000–2005
Vienna, Virginia, US	1	1986